Insider Selling: Stemline Therapeutics Inc (STML) COO Sells 25,817 Shares of Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 25,817 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total transaction of $368,408.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kenneth Hoberman also recently made the following trade(s):

  • On Monday, March 11th, Kenneth Hoberman sold 25,101 shares of Stemline Therapeutics stock. The shares were sold at an average price of $11.11, for a total transaction of $278,872.11.
  • On Thursday, March 7th, Kenneth Hoberman sold 2,995 shares of Stemline Therapeutics stock. The shares were sold at an average price of $11.36, for a total transaction of $34,023.20.
  • On Monday, February 25th, Kenneth Hoberman sold 10,557 shares of Stemline Therapeutics stock. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85.

Shares of STML traded down $0.07 during trading hours on Friday, hitting $14.55. 347,717 shares of the stock were exchanged, compared to its average volume of 679,300. Stemline Therapeutics Inc has a fifty-two week low of $7.82 and a fifty-two week high of $20.55. The company has a quick ratio of 2.97, a current ratio of 5.07 and a debt-to-equity ratio of 0.01. The stock has a market cap of $635.62 million, a PE ratio of -4.87 and a beta of 1.20.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million for the quarter, compared to the consensus estimate of $2.61 million. Sell-side analysts anticipate that Stemline Therapeutics Inc will post -2.08 EPS for the current fiscal year.

Several equities analysts have issued reports on STML shares. Roth Capital set a $33.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Friday, May 10th. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stemline Therapeutics in a research report on Friday, January 25th. ValuEngine upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 18th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $25.20.

Several institutional investors and hedge funds have recently bought and sold shares of STML. Rubric Capital Management LP acquired a new stake in shares of Stemline Therapeutics during the first quarter worth $38,614,000. Goldman Sachs Group Inc. increased its position in shares of Stemline Therapeutics by 3,363.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,363,968 shares of the biopharmaceutical company’s stock worth $17,527,000 after buying an additional 1,324,590 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Stemline Therapeutics during the first quarter worth $10,050,000. BlackRock Inc. increased its position in shares of Stemline Therapeutics by 30.9% during the first quarter. BlackRock Inc. now owns 2,703,489 shares of the biopharmaceutical company’s stock worth $34,740,000 after buying an additional 638,250 shares during the period. Finally, Man Group plc acquired a new stake in shares of Stemline Therapeutics during the first quarter worth $5,822,000. Institutional investors own 48.38% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/17/insider-selling-stemline-therapeutics-inc-stml-coo-sells-25817-shares-of-stock.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Price to Earnings Ratio (PE) Basics

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.